reports
Charles River Laboratories to Present at J.P. Morgan Healthcare Confer...
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14th, at 2:15 p.m. PT (5:15 p.m. ET). Management will present an overview of Charles River’s strategic focus, business developments, and recent trends. A live webcast of the presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at . A webcast replay will be accessible through the same website after the presentation ...
Charles River Introduces Global Biotech Incubator Program
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of the Charles River Incubator Program (CIP), specializing in supporting early-stage biotechnology companies in the discovery, development and phase-appropriate manufacturing of advanced therapies. “The Charles River Incubator Program launch, through our Global Innovation Center of Excellence, demonstrates a continued commitment to the global biotechnology industry by offering knowledge, connectivity, and priority access to the Charles River portfolio,” said Kerstin Dolp...
Charles River Laboratories to Present at Evercore ISI Investor Confere...
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the 7th Annual Evercore ISI HealthCONx Conference on Wednesday, December 4th, at 10:00 a.m. ET. Management will provide an overview of Charles River’s strategic focus, business developments, and recent trends. A live webcast of the presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at . A webcast replay will be accessible through the same website after the presentation and will rem...
Charles River Laboratories International Inc: 2 directors
A director at Charles River Laboratories International Inc gave away 4,500 shares at 0.000USD and the significance rating of the trade was 13/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors...
Charles River Laboratories to Present at UBS and Jefferies Conferences
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the UBS Global Healthcare Conference on Tuesday, November 12th, at 10:15 a.m. PT (1:15 p.m. ET), and the Jefferies London Healthcare Conference on Wednesday, November 20th, at 2:00 p.m. GMT (9:00 a.m. ET). Management will provide an overview of Charles River’s strategic focus, business developments, and recent trends. A live webcast of each presentation will be available through a link that will be posted on the Investor Relations section of the Charles Rive...
Charles River Laboratories Announces Third-Quarter 2024 Results
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 2024. For the quarter, revenue was $1.01 billion, a decrease of 1.6% from $1.03 billion in the third quarter of 2023. The impact of foreign currency translation benefited reported revenue by 0.4%, and an acquisition contributed 0.9% to consolidated third-quarter revenue. A divestiture of a small Safety Assessment site reduced reported revenue by 0.2%. Excluding the effect of these items, revenue declined 2.7% on an organic basis. On a segment basi...
Charles River Launches New Retrogenix® Non-Human Protein Library
WILMINGTON, Mass.--(BUSINESS WIRE)-- (NYSE: CRL) today announced the launch of the . The non-human protein library helps biopharmaceutical clients assess off-target binding to a non-human proteome to de-risk in vivo studies and aid in non-human species selection. “Developed in-house using the innovative and unique Retrogenix® platform, the new library provides early insights into how therapeutics interact with non-human protein targets in vitro,” said Aidan Synnott, Ph.D., Corporate Vice President, Global Discovery. “These early insights are generated without the lead time and expense associ...
Charles River Laboratories Schedules Third-Quarter 2024 Earnings Relea...
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) will release third-quarter 2024 financial results on Wednesday, November 6th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, November 6th, at 9:30 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at . A replay will be accessible through the same website. About Charles River Charles River provides essential products and services to ...
Charles River Provides Translational Expertise at Neuroscience 2024
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of neuroscience drug discovery experts will present 18 scientific posters, both independently and collaboratively with clients, at Neuroscience 2024, the annual meeting of the Society for Neuroscience (SfN). The meeting, which brings together leading researchers from across the globe, will take place from October 5-9 in Chicago, IL. “Charles River is committed to changing the course of neuroscience research,” said Antti Nurmi, Ph.D., MSc, General Manager, CNS Pharmacol...
Charles River and Lundbeck Enter Agreement Utilizing AI-Powered Logica...
WILMINGTON, Mass.--(BUSINESS WIRE)-- (NYSE: CRL) today announced an agreement with H. Lundbeck A/S (Lundbeck) to utilize to progress critical brain disease research. “We are excited to partner with Lundbeck as they work toward the discovery of novel treatments for neurodegenerative disease,” said Professor Julie Frearson, Ph.D., Senior Vice President and Chief Scientific Officer, Charles River. “Logica’s integrated, AI-augmented process allows us to be an agile partner, and combined with Lundbeck’s industry-leading neurology expertise, we look forward to a successful collaboration.” Logica...
Charles River Laboratories and CEBINA Announce Strategic Collaboration...
WILMINGTON, Mass. & VIENNA--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) and CEBINA GmbH, Central European Biotech Incubator and Accelerator, today announced a strategic collaboration within the acceleration program DanubeNeuro, an initiative focused on identifying and advancing pioneering academic research projects with the potential to create new drugs and innovative technologies in the field of neurodegeneration. CEBINA’s acceleration program identifies and develops pioneering research projects with the potential to create innovative drugs, diagnostic metho...
Charles River and Insightec Announce Strategic Collaboration to Advanc...
WILMINGTON, Mass. & MIAMI & HAIFA, Israel--(BUSINESS WIRE)-- (NYSE: CRL) and Insightec, a global healthcare company dedicated to using focused ultrasound to transform patient care, today announced the launch of a five-year strategic collaboration to provide Charles River’s clients access to a comprehensive global service and technology platform for the application of focused ultrasound (FUS) for drug discovery and preclinical development of therapeutics in neuroscience. Insightec’s novel low-frequency ultrasound platform non-invasively disrupts the blood-brain barrier, enabling drugs to be de...
Charles River Laboratories to Present at Baird and Morgan Stanley Conf...
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at two upcoming investor conferences, including: Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5th, at 9:15 a.m. EDT; and Baird 2024 Global Healthcare Conference on Tuesday, September 10th, at 10:15 a.m. EDT. Management will present an overview of Charles River’s strategic focus, business developments, and recent trends. A live webcast of each presentation will be available through a link that will be posted on the Inve...
Charles River Laboratories Announces Second-Quarter 2024 Results
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the second quarter of 2024. For the quarter, revenue was $1.03 billion, a decrease of 3.2% from $1.06 billion in the second quarter of 2023. The impact of foreign currency translation reduced reported revenue by 0.3%, a divestiture reduced reported revenue by 0.2%, and an acquisition contributed 0.5% to consolidated second-quarter revenue. Excluding the effect of these items, revenue also declined 3.2% on an organic basis. On a segment basis, organic revenue growth i...
Charles River Collaborates with Patient Advocacy Group, FOXG1 Research...
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today a collaboration with the (FRF) highlighting the patient advocacy group’s model to independently drive drug development through the clinical phase. The parent-led global organization driving the research to cure FOXG1 syndrome and related neurological disorders will collaborate with Charles River in a comprehensive gene therapy contract development and manufacturing organization (CDMO) agreement. “Charles River is proud to work with the FOXG1 Research Foundation to advance its gene...
Charles River Laboratories and Autobahn Labs Announce Collaborative Pr...
WILMINGTON, Mass. & SAN FRANCISCO--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) and Autobahn Labs, a Samsara BioCapital-backed virtual accelerator for academic biotech, today announced a collaborative relationship that establishes Charles River as the preferred research partner to support Autobahn’s growing pipeline of early-stage, preclinical therapeutics’ programs. This agreement will grant Autobahn preferred access to Charles River’s industry-standard, state-of-the-art drug discovery and development capabilities. The purpose of the partnership is to accelerat...
Charles River Laboratories Schedules Second-Quarter 2024 Earnings Rele...
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2024 financial results on Wednesday, August 7th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, August 7th, at 9:00 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at . A replay will be accessible through the same website. About Charles River Charles River provides essential products and services to ...
Charles River to Perform Plasmid Manufacturing for AAVantgarde
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) and today announced a contract development and manufacturing organization (CDMO) agreement to produce Good Manufacturing Practice- (GMP) plasmid DNA. AAVantgarde, a clinical-stage biotechnology company with two proprietary adeno-associated viral (AAV) vector platforms for large gene delivery and developing products to treat inherited retinal diseases, will leverage Charles River’s expertise in manufacturing GMP plasmid DNA. AAVantgarde has two proprietary AAV-based large gene delivery platforms, ...
Charles River Laboratories Announces Strategic Lentiviral Vector Manuf...
ROCKVILLE, Md.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) and the at the today announced a lentiviral vector contract development and manufacturing organization (CDMO) agreement. Gates Institute will leverage Charles River’s premier cell and gene therapy CDMO expertise to develop Good Manufacturing Practice (GMP)-grade lentiviral vectors (LVVs) for use in novel chimeric antigen receptor (CAR) T-cell therapies for hematological cancers. The Gates Institute mission at the University of Colorado Anschutz Medical Campus is to develop and deliver advanced ther...
Charles River and Captain T Cell Announce Plasmid DNA and Viral Vector...
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) and Captain T Cell, a spinoff from the renowned Max Delbrück Center Berlin, Germany, today announced a plasmid DNA and retrovirus vector production program agreement. As part of Charles River’s Cell and Gene Therapy (CGT) Accelerator Program (CAP), Captain T Cell will have access to established plasmid and viral vector contract development and manufacturing organization (CDMO) capabilities and advisory services ahead of Captain T Cell’s plan to manufacture a TCR-T cell therapy for solid tumor patien...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.